Loading...
Market
Global approval of semaglutide for diabetic CKD by end of 2025
5
Resolution / Starting Odds
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Global drug approval databases and announcements from health authorities
Story
FLOW Trial: Semaglutide 1.0mg Reduces Kidney, Cardiovascular Risks by 24% in Diabetic CKD Patients
May 24, 2024, 10:35 AM
The FLOW trial has shown that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of serious kidney outcomes, major cardiovascular events, and death among patients with type 2 diabetes and chronic kidney disease (CKD). The trial, which involved 3,533 participants over approximately three years, was stopped early due to its efficacy. Results indicated a 24% reduction in kidney disease progression and cardiovascular and kidney death. The study, published in NEJM, highlighted that a weekly 1.0mg dose of semaglutide was effective.
View original story
Similar markets
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Less than 10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
More than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
None • 25%
1-2 countries • 25%
3-5 countries • 25%
More than 5 countries • 25%
Approved in US and EU • 25%
Approved only in US • 25%
Approved only in EU • 25%
Not approved in US or EU • 25%
0 countries • 20%
1-3 countries • 20%
4-6 countries • 20%
7-9 countries • 20%
10 or more countries • 20%
Less than 20 countries • 33%
20-50 countries • 34%
More than 50 countries • 33%
Widely adopted • 25%
Moderately adopted • 25%
Rarely adopted • 25%
Not adopted • 25%